Analyzing real-world treatment data for advanced skin cancer patients in Europe
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
EuMelaReg gGmbH · NCT05741073
This study looks at real-world treatment experiences of people in Europe with advanced skin cancer to see how they are being treated and what outcomes they have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | EuMelaReg gGmbH (industry) |
| Drugs / interventions | radiation |
| Locations | 1 site (Brussels) |
| Trial ID | NCT05741073 on ClinicalTrials.gov |
What this trial studies
This observational registry study aims to collect and analyze real-world data on patients with advanced non-melanoma skin cancer (NMSC), specifically basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), across various European regions. By utilizing the European NMSC-Registry, the study will describe patient characteristics, treatment patterns, and outcomes in routine clinical practice. The data collected will help address critical questions regarding the management of advanced NMSC and inform future treatment strategies. The study emphasizes the importance of accurate data recording and management to ensure the reliability of findings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced NMSC who are not candidates for curative surgery or radiation.
Not a fit: Patients currently receiving treatment within a clinical trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective treatment strategies for advanced skin cancer patients, potentially improving patient outcomes.
How similar studies have performed: While real-world data studies in skin cancer are limited, similar registry-based approaches have shown promise in improving understanding of treatment patterns and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged ≥18 years at index date 2. Patients documented in the European NMSC-registry fulfilling EMR quality standard 3. Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3) Exclusion Criteria: 1\. Patients receiving treatment within a clinical trial.
Where this trial is running
Brussels
- UZ (Universitair Ziekenhuis) Brüssel — Brussels, Belgium (RECRUITING)
Study contacts
- Study coordinator: Alexandra Hansen
- Email: alexandra.hansen@eumelareg.org
- Phone: +493037026901
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma